Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025
Mareque M, Montesinos P, Font P, Guinea JM, De La Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Mansfield C, Sutphin J, Boeri M. Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question. Health Econ. 2020 Oct;29(10):1307-15. doi: 10.1002/hec.4124
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Romano (DeMuro) CD, Lewis S, Barrett A, Andersson FL, Williams V, Ancoli-Israel S, Roth T. Development of the Nocturia Sleep Quality Scale: a patient-reported outcome measure of sleep impact related to nocturia. Sleep Med. 2019 Jul;59:101-6. doi: 10.1016/j.sleep.2019.02.006
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of sleep apnoea: a systematic review and meta-analysis. Sleep Med. 2018 Feb;42:38-46. doi: 10.1016/j.sleep.2017.12.005.
Heidenreich S, Watson V, Ryan M, Phimister E. Decision heuristic or preference? Attribute non-attendance in discrete choice problems. Health Econ. 2018 Jan;27(1):157-71. doi: 10.1002/hec.3524
Dundas SJ, von Haefen RH, Mansfield C. Recreation costs of endangered species protection: evidence from Cape Hatteras National Seashore. Marine Resource Economics. 2018 Jan;33(1):1-25. doi: 10.1086/694752
Tsuchiya A, Watson V. Re-thinking “the different perspectives that can be used when eliciting preferences in health". Health Econ. 2017 Dec;26(12):e103-7. doi: 10.1002/hec.3480
Krucien N, Watson V, Ryan M. Is best-worst scaling suitable for health state valuation? A comparison with discrete choice experiments. Health Econ. 2017 Dec;26(12):e1-e16. doi: 10.1002/hec.3459
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Watson V, Becker F, de Bekker-Grob E. Discrete choice experiment response rates: a meta-analysis. Health Econ. 2017 Jun;26(6):810-7. doi: 10.1002/hec.3354
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.
Zarkin GA, Cowell AJ, Hicks KA, Mills MJ, Belenko S, Dunlap LJ, Houser KA, Keyes V. Benefits and costs of substance abuse treatment programs for state prison inmates: results from a lifetime simulation model. Health Econ. 2012 Jun;21(6):633-52.
Myers KH, Parsons GR, Edwards PET. Measuring the recreational use value of migratory shorebirds on the Delaware Bay. Marine Resource Economics. 2010 Apr 23;25(3):247-64.
Cappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, Martin SA. Measurement properties of the medical outcomes study sleep scale in patients with fibromyalgia. Sleep Med. 2009 Aug;10(7):766-70.
Ryan M, Watson V. Comparing welfare estimates from payment card contingent valuation and discrete choice experiments. Health Econ. 2009 Apr;18(4):389-401. doi: 10.1002/hec.1364
Ryan M, Watson V, Entwistle V. Rationalising the 'irrational': a think aloud study of discrete choice experiment responses. Health Econ. 2009 Mar;18(3):321-36. doi: 10.1002/hec.1369
McCrink L, Allen RP, Wolowacz SE, Sherrill B, Connolly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med. 2007 Jan 1;8(1):73-83.
Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005 Nov 1;14(11):1133-50.